Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Population Pharmacokinetic Analyses for Arbekacin After Administration of ME1100 Inhalation Solution.

Lakota EA, Sato N, Koresawa T, Kondo K, Bhavnani SM, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.00267-19. doi: 10.1128/AAC.00267-19. [Epub ahead of print]

PMID:
31182524
2.

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.

Zhang L, Wicha WW, Bhavnani SM, Rubino CM.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii27-iii34. doi: 10.1093/jac/dkz088.

3.

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.

Bhavnani SM, Zhang L, Hammel JP, Rubino CM, Bader JC, Sader HS, Gelone SP, Wicha WW, Ambrose PG.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii35-iii41. doi: 10.1093/jac/dkz089.

4.

Erratum for Lakota et al., "Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data".

Lakota EA, Ong V, Flanagan S, Rubino CM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e00333-19. doi: 10.1128/AAC.00333-19. Print 2019 Apr. No abstract available.

5.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies.

Trang M, Seroogy JD, Van Wart SA, Bhavnani SM, Kim A, Gibbons JA, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02329-18. doi: 10.1128/AAC.02329-18. Print 2019 Apr.

6.

Time for Precision: A World Without Susceptibility Breakpoints.

Bader JC, Lakota EA, Andes DR, Rubino CM, Ambrose PG, Bhavnani SM.

Open Forum Infect Dis. 2018 Oct 31;5(12):ofy282. doi: 10.1093/ofid/ofy282. eCollection 2018 Dec.

7.

Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia".

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00198-18. doi: 10.1128/AAC.00198-18. Print 2018 Apr. No abstract available.

8.

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.

Bader JC, Lakota EA, Flanagan S, Ong V, Sandison T, Rubino CM, Bhavnani SM, Ambrose PG.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02614-17. doi: 10.1128/AAC.02614-17. Print 2018 Jun.

9.

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.

Lakota EA, Ong V, Flanagan S, Rubino CM.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02603-17. doi: 10.1128/AAC.02603-17. Print 2018 Jun. Erratum in: Antimicrob Agents Chemother. 2019 Mar 27;63(4):.

10.

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):351. doi: 10.1007/s10928-018-9572-2.

PMID:
29446052
11.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02228-17. doi: 10.1128/AAC.02228-17. Print 2018 Apr.

12.

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity.

Ambrose PG, VanScoy BD, Adams J, Fikes S, Bader JC, Bhavnani SM, Rubino CM.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02257-17. doi: 10.1128/AAC.02257-17. Print 2018 Apr.

13.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.

Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02103-17. doi: 10.1128/AAC.02103-17. Print 2018 Mar.

14.

Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.

Ismail M, Lee VH, Chow CR, Rubino CM.

J Clin Pharmacol. 2018 Apr;58(4):541-548. doi: 10.1002/jcph.1044. Epub 2017 Dec 14.

PMID:
29239000
15.

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.

Greenblatt DJ, Patel M, Harmatz JS, Nicholson WT, Rubino CM, Chow CR.

J Clin Pharmacol. 2018 Apr;58(4):533-540. doi: 10.1002/jcph.1040. Epub 2017 Nov 30.

PMID:
29194698
16.

Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs.

Lakota EA, Bader JC, Rubino CM.

Curr Opin Pharmacol. 2017 Oct;36:139-145. doi: 10.1016/j.coph.2017.10.014. Epub 2017 Nov 20. Review.

PMID:
29156443
17.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01323-17. doi: 10.1128/AAC.01323-17. Print 2018 Jan. Erratum in: Antimicrob Agents Chemother. 2018 Mar 27;62(4):.

18.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.

VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

19.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.

20.

A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers.

Pan L, Belloni P, Ding HT, Wang J, Rubino CM, Putnam WS.

Adv Ther. 2017 Sep;34(9):2071-2082. doi: 10.1007/s12325-017-0594-8. Epub 2017 Aug 14.

21.

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):161-177. doi: 10.1007/s10928-017-9518-0. Epub 2017 Mar 28. Erratum in: J Pharmacokinet Pharmacodyn. 2018 Feb 14;:.

PMID:
28353185
22.

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.

Belley A, Robson R, Francis JL, Adcock DM, Tiefenbacher S, Rubino CM, Moeck G, Sylvester D, Dudley MN, Loutit J.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01968-16. doi: 10.1128/AAC.01968-16. Print 2017 Feb.

23.

Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.

Ambrose PG, VanScoy B, Conde H, McCauley J, Rubino CM, Bhavnani SM.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01605-16. doi: 10.1128/AAC.01605-16. Print 2017 Jan.

24.

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.

Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A.

Sci Transl Med. 2016 Feb 3;8(324):324ra15. doi: 10.1126/scitranslmed.aad6654.

25.

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1600-7. doi: 10.1128/AAC.02967-15.

26.

A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain.

Robinson CY, Rubino CM, Farr SJ.

J Opioid Manag. 2015 Sep-Oct;11(5):405-15. doi: 10.5055/jom.2015.0290.

PMID:
26535968
27.
28.

Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.

Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG.

Antimicrob Agents Chemother. 2015;59(6):3365-72. doi: 10.1128/AAC.00176-15. Epub 2015 Mar 30.

29.

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers.

Farr SJ, Robinson CY, Rubino CM.

Clin Pharmacol. 2015 Jan 19;7:1-9. doi: 10.2147/CPAA.S70831. eCollection 2015.

30.

Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age.

Bradley JS, Puttagunta S, Rubino CM, Blumer JL, Dunne M, Sullivan JE.

Pediatr Infect Dis J. 2015 Jul;34(7):748-52. doi: 10.1097/INF.0000000000000646.

PMID:
25551831
31.

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):372-80. doi: 10.1128/AAC.02531-14. Epub 2014 Nov 3.

32.

Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.

Rubino CM, Xue B, Bhavnani SM, Prince WT, Ivezic-Schoenfeld Z, Wicha WW, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):282-8. doi: 10.1128/AAC.02033-13. Epub 2014 Oct 27.

33.

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.

Antimicrob Agents Chemother. 2014;58(2):885-91. doi: 10.1128/AAC.01680-13. Epub 2013 Nov 25.

34.

Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):6348-50. doi: 10.1128/AAC.01748-13. Epub 2013 Sep 16.

35.

Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor.

Raddad E, Melhem MR, Sloan-Lancaster JS, Miller JW, Van Wart SA, Rubino CM.

CPT Pharmacometrics Syst Pharmacol. 2013 Aug 21;2:e66. doi: 10.1038/psp.2013.43.

36.

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.

Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Reynolds DK, Riccobene T, Ambrose PG.

J Clin Pharmacol. 2013 Nov;53(11):1155-67. doi: 10.1002/jcph.153. Epub 2013 Aug 14.

PMID:
23907740
37.

Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules.

Melhem MR, Rubino CM, Farr SJ, Robinson CY.

Clin Pharmacokinet. 2013 Oct;52(10):907-17. doi: 10.1007/s40262-013-0081-6.

PMID:
23719682
38.

New EMA guideline for antimicrobial development.

Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL.

Lancet Infect Dis. 2012 Apr;12(4):265-6. doi: 10.1016/S1473-3099(12)70046-4. No abstract available.

PMID:
22459079
39.

Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.

Ambrose PG, Hammel JP, Bhavnani SM, Rubino CM, Ellis-Grosse EJ, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1466-70. doi: 10.1128/AAC.01743-10. Epub 2011 Dec 12.

40.

Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.

Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, Korth-Bradley J, Ambrose PG.

Antimicrob Agents Chemother. 2012 Feb;56(2):1065-72. doi: 10.1128/AAC.01615-10. Epub 2011 Dec 5.

41.

Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.

Rubino CM, Bhavnani SM, Forrest A, Dukart G, Dartois N, Cooper A, Korth-Bradley J, Ambrose PG.

Antimicrob Agents Chemother. 2012 Jan;56(1):130-6. doi: 10.1128/AAC.00277-10. Epub 2011 Oct 3.

42.

Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.

Rubino CM, Forrest A, Bhavnani SM, Dukart G, Cooper A, Korth-Bradley J, Ambrose PG.

Antimicrob Agents Chemother. 2010 Dec;54(12):5180-6. doi: 10.1128/AAC.01414-09. Epub 2010 Oct 4.

43.

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL.

Clin Infect Dis. 2010 Jun 15;50(12):1568-74. doi: 10.1086/652767.

PMID:
20462352
44.

Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.

Gill SC, Rubino CM, Bassett J, Miller L, Ambrose PG, Bhavnani SM, Beaudry A, Li J, Stone KC, Critchley I, Janjic N, Heine HS.

Antimicrob Agents Chemother. 2010 May;54(5):1678-83. doi: 10.1128/AAC.00737-08. Epub 2010 Feb 9.

45.

Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.

Bhavnani SM, Rubino CM, Ambrose PG, Babinchak TJ, Korth-Bradley JM, Drusano GL.

Antimicrob Agents Chemother. 2010 Mar;54(3):1207-12. doi: 10.1128/AAC.00182-09. Epub 2009 Dec 28.

46.

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.

Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A.

Antimicrob Agents Chemother. 2009 Oct;53(10):4422-8. doi: 10.1128/AAC.00231-09. Epub 2009 Jul 27.

47.

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS.

Pulm Pharmacol Ther. 2009 Aug;22(4):279-85. doi: 10.1016/j.pupt.2009.03.003. Epub 2009 Mar 27.

PMID:
19328861
48.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse E.

Diagn Microbiol Infect Dis. 2009 Jan;63(1):38-42. doi: 10.1016/j.diagmicrobio.2008.09.014.

PMID:
19073300
49.

Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.

Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG.

Diagn Microbiol Infect Dis. 2008 Sep;62(1):99-101. doi: 10.1016/j.diagmicrobio.2008.04.008. Epub 2008 Jun 25.

PMID:
18583085
50.

Supplemental Content

Loading ...
Support Center